Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
Ann Intern Med
    April 2026
  1. ALBALOUL H, Nemer A, Saini N, Schuster MG, et al
    Infectious Diseases: What You May Have Missed in 2025.
    Ann Intern Med. 2026 Apr 14:e2600983. doi: 10.7326/ANNALS-26-00983.
    >> Share

    February 2026
  2. QASEEM A, Obley AJ, Yost J, Abraham GM, et al
    Outpatient Treatment of Confirmed COVID-19 in Symptomatic Adults: Living, Rapid Practice Points From the American College of Physicians (Version 3).
    Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03766.
    >> Share

  3. SOMMER I, Dobrescu A, Gadinger A, Sharifan A, et al
    Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Review for the American College of Physicians (Version 3).
    Ann Intern Med. 2026 Feb 10. doi: 10.7326/ANNALS-25-03691.
    >> Share

    December 2025
  4. COLSON AE, Crofoot GE, Ruane PJ, Ramgopal MN, et al
    Once-Weekly Oral Islatravir Plus Lenacapavir Versus Daily Oral Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Persons With HIV-1 : A Phase 2 Randomized Study.
    Ann Intern Med. 2025 Dec 23. doi: 10.7326/ANNALS-25-01939.
    >> Share

    April 2025
  5. ZAR FA
    In men and gender-diverse persons, twice-yearly subcutaneous lenacapavir vs. daily oral F/TDF reduced HIV incidence.
    Ann Intern Med. 2025 Apr 1. doi: 10.7326/ANNALS-25-00552.
    >> Share

    October 2024
  6. MAKI DG
    In adults with postacute sequelae of COVID-19, nirmatrelvir-ritonavir did not improve symptoms at 10 wk.
    Ann Intern Med. 2024 Oct 1. doi: 10.7326/ANNALS-24-02172.
    >> Share

    February 2024

  7. Correction: SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy.
    Ann Intern Med. 2024 Feb 20. doi: 10.7326/L24-0045.
    >> Share

    January 2024
  8. CHAGLA Z
    In outpatients with COVID-19 during Omicron variant circulation, molnupiravir and nirmatrelvir-ritonavir improved outcomes.
    Ann Intern Med. 2024 Jan 2. doi: 10.7326/J23-0108.
    >> Share

  9. CENTOR RM, Cohen MS
    Annals On Call - COVID-19 Rebound After Nirmatrelvir-Ritonavir Treatment.
    Ann Intern Med. 2024;177:eA230002.
    >> Share

    November 2023
  10. COHEN MS, Brown ER
    Rebound of COVID-19 With Nirmatrelvir-Ritonavir Antiviral Therapy.
    Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-2887.
    >> Share

  11. EDELSTEIN GE, Boucau J, Uddin R, Marino C, et al
    SARS-CoV-2 Virologic Rebound With Nirmatrelvir-Ritonavir Therapy : An Observational Study.
    Ann Intern Med. 2023 Nov 14. doi: 10.7326/M23-1756.
    >> Share

    October 2023
  12. IOANNOU GN, Berry K, Rajeevan N, Li Y, et al
    Effectiveness of Nirmatrelvir-Ritonavir Against the Development of Post-COVID-19 Conditions Among U.S. Veterans : A Target Trial Emulation.
    Ann Intern Med. 2023 Oct 31. doi: 10.7326/M23-1394.
    >> Share

  13. FOCOSI D, Nicastri E
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.
    Ann Intern Med. 2023;176:eL230264.
    >> Share

  14. WAN EYF, Yan VKC, Mok AHY, Wong ICK, et al
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19.
    Ann Intern Med. 2023;176:eL230265.
    >> Share

    September 2023
  15. SOMMER I, Ledinger D, Thaler K, Dobrescu A, et al
    Outpatient Treatment of Confirmed COVID-19: A Living, Rapid Evidence Review for the American College of Physicians (Version 2).
    Ann Intern Med. 2023 Sep 19. doi: 10.7326/M23-1626.
    >> Share

  16. QASEEM A, Yost J, Abraham GM, Andrews R, et al
    Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 2).
    Ann Intern Med. 2023 Sep 19. doi: 10.7326/M23-1636.
    >> Share

    June 2023
  17. BAJEMA KL, Berry K, Streja E, Rajeevan N, et al
    Effectiveness of COVID-19 Treatment With Nirmatrelvir-Ritonavir or Molnupiravir Among U.S. Veterans: Target Trial Emulation Studies With One-Month and Six-Month Outcomes.
    Ann Intern Med. 2023 Jun 6:M22-3565. doi: 10.7326/M22-3565.
    >> Share

    March 2023
  18. HERNAN MA, Del Amo J
    Drug Repurposing and Observational Studies: The Case of Antivirals for the Treatment of COVID-19.
    Ann Intern Med. 2023 Mar 28. doi: 10.7326/M22-3582.
    >> Share

  19. WAN EYF, Yan VKC, Mok AHY, Wang B, et al
    Effectiveness of Molnupiravir and Nirmatrelvir-Ritonavir in Hospitalized Patients With COVID-19 : A Target Trial Emulation Study.
    Ann Intern Med. 2023 Mar 14. doi: 10.7326/M22-3057.
    >> Share

    February 2023
  20. DEO R, Choudhary MC, Moser C, Ritz J, et al
    Symptom and Viral Rebound in Untreated SARS-CoV-2 Infection.
    Ann Intern Med. 2023 Feb 21. doi: 10.7326/M22-2381.
    >> Share

    December 2022
  21. DRYDEN-PETERSON S, Kim A, Kim AY, Caniglia EC, et al
    Nirmatrelvir Plus Ritonavir for Early COVID-19 in a Large U.S. Health System : A Population-Based Cohort Study.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-2141.
    >> Share

  22. ANESI GL, Maguire C
    Nirmatrelvir Plus Ritonavir for Ambulatory COVID-19: Expanding Evidence, Expanding Role.
    Ann Intern Med. 2022 Dec 13. doi: 10.7326/M22-3427.
    >> Share

    November 2022
  23. QASEEM A, Yost J, Miller MC, Andrews R, et al
    Outpatient Treatment of Confirmed COVID-19: Living, Rapid Practice Points From the American College of Physicians (Version 1).
    Ann Intern Med. 2022 Nov 29. doi: 10.7326/M22-2249.
    >> Share

  24. SOMMER I, Dobrescu A, Ledinger D, Moser I, et al
    Outpatient Treatment of Confirmed COVID-19 : A Living, Rapid Review for the American College of Physicians.
    Ann Intern Med. 2022 Nov 29. doi: 10.7326/M22-2202.
    >> Share

    June 2022
  25. VASSILOPOULOS A, Mylonakis E
    In patients with COVID-19 at risk for severe disease, nirmatrelvir + ritonavir reduced hospitalization or death.
    Ann Intern Med. 2022 Jun 7. doi: 10.7326/J22-0038.
    >> Share

    March 2022
  26. MARZOLINI C, Kuritzkes DR, Marra F, Boyle A, et al
    Prescribing Nirmatrelvir-Ritonavir: How to Recognize and Manage Drug-Drug Interactions.
    Ann Intern Med. 2022 Mar 1. doi: 10.7326/M22-0281.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016